EPIRUS Biopharma (EPRS) Tops Q4 EPS by 19c

EPIRUS Biopharma (NASDAQ: EPRS) reported Q4 EPS of ($0.80), $0.19 better than the analyst estimate of ($0.99).

For earnings history and earnings-related data on EPIRUS Biopharma (EPRS) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• GLJ Research on Sell Rated Tesla (TSLA): 'We now see FSD as the main reason TSLA’s stock will bleed lower this year'